Ratings Shanghai Henlius Biotech, Inc. OTC Markets

Equities

SGBCF

CNE100003N76

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

05-14	Shanghai Henlius Biotech Gets Go-Ahead for Clinical Trials of Breast Cancer Drug in China	MT
05-14	Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration	CI

Strengths

Over the last twelve months, the sales forecast has been frequently revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SHANGHAI HENLIUS BIOTECH, INC.	-.--%	1.27B	-
CSL LIMITED	-2.32%	92.59B	A-
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.43B	A-
BIOGEN INC.	-10.96%	33.49B	B-
BIOMARIN PHARMACEUTICAL INC.	-20.05%	14.62B	C
INCYTE CORPORATION	-9.06%	12.77B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.58B	D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.35B	B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.97B	B+
INNOVENT BIOLOGICS, INC.	-6.32%	8.3B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes